Skyhawk, Announces

Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

Veröffentlicht: 19.03.2026 um 22:51 Uhr, prnewswire.co.uk

Skyhawk Therapeutics Massachusetts

en | boerse | 68905785 |